About: Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection
Creator	He, Biao Perlman, Stanley Li, Kun Channappanavar, Rudragouda Wohlford-Lenane, Christine Meyerholz, David An, Dong Li, Zhuo Mccray, Paul
Source	Medline; PMC
abstract	Middle East respiratory syndrome coronavirus (MERS-CoV) can cause severe and fatal acute respiratory disease in humans and remains endemic in the Middle East since first being identified in 2012. There are currently no approved vaccines or therapies available for MERS-CoV. In this study, we evaluated parainfluenza virus 5 (PIV5)-based vaccine expressing the MERS-CoV envelope spike protein (PIV5/MERS-S) in a human DPP4 knockin C57BL/6 congenic mouse model (hDPP4 KI). Following a single-dose intranasal immunization, PIV5-MERS-S induced neutralizing antibody and robust T cell responses in hDPP4 KI mice. A single intranasal administration of 10(4) PFU PIV5-MERS-S provided complete protection against a lethal challenge with mouse-adapted MERS-CoV (MERS(MA)6.1.2) and improved virus clearance in the lung. In comparison, single-dose intramuscular immunization with 10(6) PFU UV-inactivated MERS(MA)6.1.2 mixed with Imject alum provided protection to only 25% of immunized mice. Intriguingly, an influx of eosinophils was observed only in the lungs of mice immunized with inactivated MERS-CoV, suggestive of a hypersensitivity-type response. Overall, our study indicated that PIV5-MERS-S is a promising effective vaccine candidate against MERS-CoV infection.
has issue date	2020-04-07(xsd:dateTime)
bibo:doi	10.1128/mbio.00554-20
bibo:pmid	32265331
has license	cc-by
sha1sum (hex)	9517ad2f875609944240d775fa528dcc95d9e19d
schema:url	https://doi.org/10.1128/mbio.00554-20
resource representing a document's title	Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection
has PubMed Central identifier	PMC7157776
has PubMed identifier	32265331
schema:publication	mBio
resource representing a document's body	covid:9517ad2f875609944240d775fa528dcc95d9e19d#body_text
is schema:about of	named entity 'response' named entity 'MERS-CoV' named entity 'protein' named entity 'coronavirus' named entity 'emerging' named entity 'human' named entity 'vaccine' named entity 'MERS-CoV' named entity 'infection' named entity 'intramuscular' named entity 'Mice' named entity 'Protein' named entity 'based' named entity 'neutralizing antibody' named entity 'lethal' named entity 'vaccines' named entity 'therapies' named entity 'SARS-CoV-2' named entity 'MERS' named entity 'MERS' named entity 'lungs' named entity 'MERS-CoV' named entity 'clearance' named entity 'complete' named entity 'Intranasal' named entity 'intranasal administration' named entity 'vaccine' named entity 'endemic' named entity 'hypersensitivity' named entity 'MERS-CoV' named entity 'lungs' named entity 'intranasal' named entity 'vaccine' named entity 'MERS-CoV' named entity 'immunization' named entity 'respiratory disease' named entity 'MERS-CoV' named entity 'Recombinant' named entity 'eosinophils' named entity 'homogenizer' named entity 'immune responses' named entity 'gene' named entity 'MERS' named entity 'edema' named entity 'eosinophils' named entity 'DMEM' named entity 'Vero cells' named entity 'glycoprotein' named entity 'regulatory sequences' named entity 'CD45' named entity 'protein' named entity 'infection' named entity 'zoonotic' named entity 'immune responses' named entity 'serially diluted' named entity 'intranasally' named entity 'Specific-pathogen-free' named entity 'virus' named entity 'lungs' named entity 'MERS-CoV' named entity 'lung' named entity 'necrotic' named entity 'hypersensitivity' named entity 'MERS-CoV' named entity 'lung' named entity 'MERS-CoV' named entity 'immune responses' named entity 'hyaline' named entity 'vaccine' named entity 'MERS-CoV' named entity 'formalin' named entity 'Neutralizing antibody' named entity 'CD8 T cell'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software